Document is current
Any future updates will be listed below
-
Authors
Lioudyno, Maria I.
Sevrioukov, Evgueni A.
Olivarria, Gema M.
Hitchcock, Lauren
Javonillo, Dominic I.
Campos, Sydney M.
Rivera, Isabel
Wright, Sierra T.
Head, Elizabeth
Fortea, Juan
Wisniewski, Thomas
Cuello, A. Claudio
Do Carmo, Sonia
Lane, Thomas E.
Busciglio, Jorge
-
Funding
Funding for this research was provided by:
US National Institutes of Health (5T32 AI007319-33, T32 T32NS121727, P30AG066519, RO1AG056850, RO1AG056850, RO1AG056850, RO1AG056850)
National Institutes of Health (T32 AG000096)
Instituto de Salud Carlos III (INT21/00073)
Horizon 2020–Research and Innovation Framework Programme from the European Union (H2020-SC1-BHC-2018-2020)
Centro de Investigación Biomédica en Red sobre Enfermedades (IIBSP-DOW-2020-151)
ALZ Discovery grant from the Alzheimer’s Association (1051950)
- License Information
-
More Information
Article History
Received: 10 October 2024
Revised: 13 May 2025
Accepted: 14 May 2025
First Online: 30 May 2025
Declarations
:
: Conflict of interest J.F. reported receiving personal fees for service on the advisory boards, adjudication committees or speaker honoraria from AC Immune, Adamed, Alzheon, Biogen, Eisai, Esteve, Fujirebio, Ionis, Laboratorios Carnot, Life Molecular Imaging, Lilly, Lundbeck, Perha, Roche, Zambón and outside the submitted work. J.F. reports holding a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx, EPI8382175.0). Other authors declare no conflict of interest.
